Literature DB >> 12879008

The oncogenic fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) induces two distinct malignant phenotypes in a murine retroviral transplantation model.

Cornelius Miething1, Rebekka Grundler, Falco Fend, Josef Hoepfl, Claudia Mugler, Christoph von Schilling, Stephan W Morris, Christian Peschel, Justus Duyster.   

Abstract

A t(2;5) (p23;q35) chromosomal translocation can be found in a high percentage of anaplastic large-cell lymphomas (ALCL). This genetic abnormality leads to the expression of the NPM-ALK fusion protein, which encodes a constitutively active tyrosine kinase that plays a causative role in lymphomagenesis. Employing a modified infection/transplantation protocol utilizing an MSCV-based vector, we were able to reproducibly induce two phenotypically different lymphoma-like diseases dependent on the retroviral titers used. The first phenotype presented as a polyclonal histiocytic malignancy of myeloid/macrophage origin with a short latency period of 3-4 weeks. Clinically, the diseased mice showed rapidly progressive wasting, lymphadenopathy and pancytopenia. Mice displaying the second phenotype developed monoclonal B-lymphoid tumors with a longer latency of approximately 12-16 weeks, primarily involving the spleen and the bone marrow, with less extensive lymph node but also histologically evident extranodal organ infiltration by large immature plasmoblastic cells. The described retroviral mouse model will be useful to analyse the role of NPM-ALK in lymphomagenesis in vivo and may contribute to the development of new treatment options for NPM-ALK induced malignancies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12879008     DOI: 10.1038/sj.onc.1206575

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  13 in total

Review 1.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 2.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

3.  NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma.

Authors:  Annamaria Galietta; Rosalind H Gunby; Sara Redaelli; Paola Stano; Cristiana Carniti; Angela Bachi; Philip W Tucker; Carmen J Tartari; Ching-Jung Huang; Emanuela Colombo; Karen Pulford; Miriam Puttini; Rocco G Piazza; Holger Ruchatz; Antonello Villa; Arianna Donella-Deana; Oriano Marin; Danilo Perrotti; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2007-05-30       Impact factor: 22.113

4.  Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma.

Authors:  Stephan Mathas; Stephan Kreher; Karen J Meaburn; Korinna Jöhrens; Björn Lamprecht; Chalid Assaf; Wolfram Sterry; Marshall E Kadin; Masanori Daibata; Stefan Joos; Michael Hummel; Harald Stein; Martin Janz; Ioannis Anagnostopoulos; Evelin Schrock; Tom Misteli; Bernd Dörken
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-25       Impact factor: 11.205

5.  Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements.

Authors:  Rebecca A Luchtel; Surendra Dasari; Naoki Oishi; Martin Bjerregård Pedersen; Guangzhen Hu; Karen L Rech; Rhett P Ketterling; Jagmohan Sidhu; Xueju Wang; Ryohei Katoh; Ahmet Dogan; N Sertac Kip; Julie M Cunningham; Zhifu Sun; Saurabh Baheti; Julie C Porcher; Jonathan W Said; Liuyan Jiang; Stephen Jacques Hamilton-Dutoit; Michael Boe Møller; Peter Nørgaard; N Nora Bennani; Wee-Joo Chng; Gaofeng Huang; Brian K Link; Fabio Facchetti; James R Cerhan; Francesco d'Amore; Stephen M Ansell; Andrew L Feldman
Journal:  Blood       Date:  2018-08-09       Impact factor: 22.113

6.  GP130 activation induces myeloma and collaborates with MYC.

Authors:  Tobias Dechow; Sabine Steidle; Katharina S Götze; Martina Rudelius; Kerstin Behnke; Konstanze Pechloff; Susanne Kratzat; Lars Bullinger; Falko Fend; Valeria Soberon; Nadya Mitova; Zhoulei Li; Markus Thaler; Jan Bauer; Elke Pietschmann; Corinna Albers; Rebekka Grundler; Marc Schmidt-Supprian; Jürgen Ruland; Christian Peschel; Justus Duyster; Stefan Rose-John; Florian Bassermann; Ulrich Keller
Journal:  J Clin Invest       Date:  2014-11-10       Impact factor: 14.808

7.  Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells.

Authors:  Lin Qiu; Raymond Lai; Quan Lin; Esther Lau; David M Thomazy; Daniel Calame; Richard J Ford; Larry W Kwak; Robert A Kirken; Hesham M Amin
Journal:  Blood       Date:  2006-06-08       Impact factor: 22.113

8.  A homozygous CARD9 mutation in a family with susceptibility to fungal infections.

Authors:  Erik-Oliver Glocker; Andre Hennigs; Mohammad Nabavi; Alejandro A Schäffer; Cristina Woellner; Ulrich Salzer; Dietmar Pfeifer; Hendrik Veelken; Klaus Warnatz; Fariba Tahami; Sarah Jamal; Annabelle Manguiat; Nima Rezaei; Ali Akbar Amirzargar; Alessandro Plebani; Nicole Hannesschläger; Olaf Gross; Jürgen Ruland; Bodo Grimbacher
Journal:  N Engl J Med       Date:  2009-10-29       Impact factor: 91.245

9.  Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment.

Authors:  Cornelius Miething; Rebekka Grundler; Claudia Mugler; Simone Brero; Josef Hoepfl; Jochen Geigl; Michael R Speicher; Oliver Ottmann; Christian Peschel; Justus Duyster
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

10.  Lineage-specific STAT5 target gene activation in hematopoietic progenitor cells predicts the FLT3(+)-mediated leukemic phenotype.

Authors:  T A Müller; R Grundler; R Istvanffy; M Rudelius; L Hennighausen; A L Illert; J Duyster
Journal:  Leukemia       Date:  2016-04-05       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.